WallStSmart

Edwards Lifesciences Corp (EW)vsTandem Diabetes Care Inc (TNDM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 498% more annual revenue ($6.07B vs $1.01B). EW leads profitability with a 17.7% profit margin vs -20.2%. EW earns a higher WallStSmart Score of 55/100 (C).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9

TNDM

Avoid

27

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 5.0Quality: 4.0
Piotroski: 3/9Altman Z: -0.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWSignificantly Overvalued (-544.4%)

Margin of Safety

-544.4%

Fair Value

$12.31

Current Price

$82.67

$70.36 premium

UndervaluedFair: $12.31Overvalued

Intrinsic value data unavailable for TNDM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

TNDM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.7x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

TNDM4 concerns · Avg: 3.5/10
Price/BookValuation
10.7x4/10

Trading at 10.7x book value

Revenue GrowthGrowth
2.7%4/10

2.7% revenue growth

Market CapQuality
$1.66B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
2.9%3/10

Operating margin of 2.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bull Case : TNDM

TNDM has a balanced fundamental profile.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.

Bear Case : TNDM

The primary concerns for TNDM are Price/Book, Revenue Growth, Market Cap. Debt-to-equity of 3.64 is elevated, increasing financial risk.

Key Dynamics to Monitor

EW profiles as a mature stock while TNDM is a turnaround play — different risk/reward profiles.

TNDM carries more volatility with a beta of 1.67 — expect wider price swings.

EW is growing revenue faster at 13.3% — sustainability is the question.

EW generates stronger free cash flow (354M), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 27/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Tandem Diabetes Care Inc

HEALTHCARE · MEDICAL DEVICES · USA

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and markets various products for people with insulin-dependent diabetes in the United States. The company is headquartered in San Diego, California.

Visit Website →

Want to dig deeper into these stocks?